News MSD adds bispecific cancer antibody via $1.3bn Curon deal MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies.
Deep Dive Moving from autologous to allogeneic ACT paradigms We have come so far in a relatively short time with Adoptive Cellular Transfer (ACT).
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
